Table 2.
Anticancer activity of synthesized compounds
Compound code |
|
|
IC50 of cell line types (tissue/cell) |
|||
---|---|---|---|---|---|---|
|
THP-1 |
A-549 |
MCF-7 |
IGROV-1 |
HEP-2 |
DU-145 |
(WBC) | (lung) | (breast) | (ovary) | (liver) | (prostrate) | |
2a |
>100 |
>100 |
86.9 |
>100 |
>100 |
>100 |
2b |
>100 |
>100 |
>100 |
>100 |
- |
- |
2c |
89.2 |
71.0 |
>100 |
>100 |
- |
- |
2d |
0.80 |
>100 |
0.37 |
38.0 |
63.4 |
40.4 |
2e |
73.0 |
>100 |
>100 |
>100 |
- |
- |
2f |
81.3 |
>100 |
>100 |
>100 |
>100 |
>100 |
2 g |
70.6 |
>100 |
>100 |
- |
89 |
>100 |
2 h |
>100 |
>100 |
>100 |
- |
>100 |
- |
2i |
- |
- |
>100 |
- |
- |
- |
2j |
>100 |
>100 |
76.1 |
- |
- |
16.4 |
2 k |
>100 |
>100 |
50.0 |
- |
- |
43.9 |
2 l |
86.0 |
>100 |
76.4 |
>100 |
>100 |
>100 |
2 m |
67.0 |
75.7 |
>100 |
>100 |
>100 |
>100 |
2n |
>100 |
>100 |
>100 |
>100 |
- |
- |
2o |
>100 |
>100 |
>100 |
>100 |
- |
- |
2p |
>100 |
>100 |
>100 |
>100 |
- |
- |
2q |
68.0 |
>100 |
79.0 |
>100 |
>100 |
>100 |
2r |
40.8 |
38.7 |
51.9 |
>100 |
>100 |
>100 |
2 s |
>100 |
90.3 |
>100 |
>100 |
>100 |
>100 |
2 t |
- |
>100 |
>100 |
- |
>100 |
>100 |
2u |
>100 |
>100 |
>100 |
>100 |
>100 |
>100 |
2v |
>100 |
>100 |
95.2 |
>100 |
- |
- |
2w |
>100 |
>100 |
51.8 |
>100 |
- |
- |
2x |
92.0 |
>100 |
>100 |
>100 |
>100 |
>100 |
2y |
81.8 |
49.8 |
3.6 |
>100 |
85.3 |
- |
Adriamycin |
0.12 |
0.11 |
0.16 |
0.19 |
- |
- |
Mitomycin |
0.23 |
0.19 |
0.27 |
0.25 |
0.31 |
- |
Paclitaxel |
0.15 |
- |
- |
0.15 |
0.14 |
- |
5-fluorouracil | 9.7 | 8.6 | 9.9 | 8.3 | 9.7 | 9.1 |